Prostate Cancer Market: How Are Novel Hormonal Therapies Reshaping Treatment?
Next-generation androgen receptor pathway inhibitors — enzalutamide (Xtandi), apalutamide (Erleada), darolutamide (Nubeqa), and abiraterone (Zytiga/Yonsa) — have transformed metastatic prostate cancer management from basic ADT toward multi-combination hormonal intensification, with the Prostate Cancer Market reflecting ARPI intensification as the dominant commercial treatment...
0 Комментарии 0 Поделились 6 Просмотры 0 предпросмотр